The use of Ki-67 and anti-cytokeratin antibody(34βE12) in the differential diagnosis of prostate cancer

Objective To study the role of Ki- 67 and anti- cytokeratin antibody 34βE12 in the differential diagnosis of prostate cancers. Methods 24 cases of prostate carcinoma and 30 cases of benign prostate hyperplasia were studied with immunohistochemical technique(SP). Results In 24 prostate cancers the average Ki- 67 index was 0.45±0.21, and that in 30 cases of benign hyperplasia was 0.12±0.09, the expression of Ki- 67 is higher in prostate carcinoma than benign prostate hyperplasia, there was static significance (P 0.01). 34βE12 expression was negative in all prostate cancers, but 34βE12 expression is positive in all benign hyperplasia patients(P 0.001). Conclusions Ki- 67 expression is significantly higher in prostate cancer than in benign hyperplasia patients. 34βE12 is negative in cancer patients but is positive in benign hyperplasia patients. The combined detection of Ki- 67 and 34βE12 is very useful in the differential diagnosis of prostate diseases.